Generic-Drug Companies to Face First Charges in U.S. Probe
- Antitrust prosecutors near indictments in price-fixing case
- Mylan headquarters searched by law enforcement in 2016
Trump vs. Big Pharma: Can He Bring Drug Prices Down?
This article is for subscribers only.
U.S. prosecutors are nearing their first charges against companies in an almost four-year-old criminal investigation into alleged price-fixing by generic-drug makers, according to people familiar with the matter.
At least two companies are on track to be indicted in the coming months, in addition to several executives, said two people, who spoke on condition of anonymity because the investigation is confidential. Another company could agree to plead guilty before then, said one the people.